TriSalus Life Sciences (TLSI) Common Equity (2020 - 2026)

TriSalus Life Sciences' Common Equity history runs 7 years deep, the most recent figure standing at $12.8 million for Q1 2026.

• On a quarterly basis, Common Equity rose 137.26% year-over-year to $12.8 million in Q1 2026; TTM through Mar 2026 was $12.8 million, a 137.26% increase from a year earlier, with the FY2025 full-year figure at -$33.9 million, down 30.77% from the prior year.
• Common Equity advanced to $12.8 million in Q1 2026 per TLSI's latest filing, from -$33.9 million in the prior quarter.
• Across five years, Common Equity topped out at $12.8 million in Q1 2026 and bottomed at -$198.4 million in Q2 2023.
• The 5-year median for Common Equity is -$33.9 million (2025), against an average of -$72.1 million.
• Across the five-year window, Common Equity plunged 684.82% in 2022 and jumped 137.26% in 2026, its largest moves.
• Year by year, Common Equity stood at -$177.1 million in 2022, then soared by 84.72% to -$27.1 million in 2023, then increased by 4.33% to -$25.9 million in 2024, then plunged by 30.77% to -$33.9 million in 2025, then jumped by 137.82% to $12.8 million in 2026.
• Per Business Quant, the three latest TLSI Common Equity figures stand at $12.8 million (Q1 2026), -$33.9 million (Q4 2025), and -$26.7 million (Q3 2025).